The independent medical news service

The addition of gonadotropin-releasing hormone analog to tamoxifen or an aromatase inhibitor decreases estradiol levels of men with hormone receptor-positive breast cancer, phase 2 trial data show.

Breast cancer screening by clinical breast examination is a viable approach in low and middle income countries, suggests an Indian cluster randomized controlled trial.

US researchers have developed the Cancer and Aging Research Group–Breast Cancer score to help predict grade 3–5 chemotherapy-related toxicities in older patients with early-stage breast cancer.

Black women with breast cancer are more likely than non-Hispanic White women to have a high-risk 21-gene Oncotype DX Breast Recurrence Score, and are more likely to die of breast cancer than their non-Hispanic White counterparts with a comparable score, US research shows.

The total number of radiotherapy courses delivered in England fell significantly during the first peak of the COVID-19 pandemic but this was accompanied by a rapid increase in the use of hypofractionated regimens, study data show.

Two independent studies presented at the IASLC 2020 World Conference on Lung Cancer have highlighted the heightened psychological distress experienced by patients with cancer – especially those with lung cancer – during the COVID-19 pandemic.

Treatment with the novel HER2-targeted agent margetuximab improves the outcomes of heavily pretreated patients with HER2-positive advanced breast cancer, indicate phase 3 trial results.

Two analyses have provided population-level estimates of the risk for breast cancer associated with known or suspected susceptibility genes.

The risk for osteonecrosis of the jaw following zoledronic acid treatment in patients with bone metastases is associated with cancer type, oral health, and dosing frequency, US researchers report.

Statin use is associated with a reduced risk for heart failure in women with early breast cancer receiving anthracycline- or trastuzumab-based chemotherapy, report Canadian researchers.

Palbociclib plus endocrine therapy does not improve progression-free survival compared with capecitabine in women with aromatase inhibitor-resistant metastatic breast cancer, results of the phase 3 PEARL study show.

The beneficial survival outcomes and low toxicity associated with stereotactic ablative body radiotherapy in patients with extracranial oligometastases persist in the real-world setting.

Subcutaneous administration of pertuzumab and trastuzumab generates similar pertuzumab serum trough concentrations to those seen with intravenous pertuzumab plus trastuzumab in women with HER2-positive breast cancer, research shows.

The results of a meta-analysis point to a link between PARP inhibitor use and a small increase in the risk for developing myelodysplastic syndrome and acute myeloid leukemia.

Maintenance therapy with low-dose capecitabine significantly reduces the risk for relapse or death in women with early-stage triple-negative breast cancer, show data from the phase 3 SYSUCC-001 trial.

The health-related quality of life of patients with ductal carcinoma in situ or invasive breast cancer is impaired by their prognosis and treatment, and measuring the extent of impairment could help predict mortality risk, research suggests.

Read more about these decisions here

Click through to find out more about the approved drugs

Beneficial outcomes with pembrolizumab plus chemotherapy persist with different types of chemotherapy in patients with previously untreated, locally recurrent, inoperable, or metastatic triple-negative breast cancer, exploratory analysis of the KEYNOTE-355 trial suggests.

Combined treatment with durvalumab plus bevacizumab could benefit women with HER2-negative advanced breast cancer who have progressed on bevacizumab maintenance, shows a phase 1b trial.